IL157955A0 - Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp - Google Patents

Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Info

Publication number
IL157955A0
IL157955A0 IL15795502A IL15795502A IL157955A0 IL 157955 A0 IL157955 A0 IL 157955A0 IL 15795502 A IL15795502 A IL 15795502A IL 15795502 A IL15795502 A IL 15795502A IL 157955 A0 IL157955 A0 IL 157955A0
Authority
IL
Israel
Prior art keywords
drug
alpha
methylpropiono
fluorophenylsulphonyl
toluidide
Prior art date
Application number
IL15795502A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27354679&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL157955(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE0101171A external-priority patent/SE0101171D0/xx
Priority claimed from SE0102957A external-priority patent/SE0102957D0/xx
Priority claimed from SE0103565A external-priority patent/SE0103565D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IL157955A0 publication Critical patent/IL157955A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL15795502A 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp IL157955A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0101171A SE0101171D0 (sv) 2001-04-02 2001-04-02 Pharmaceutical formulation
SE0102957A SE0102957D0 (sv) 2001-09-04 2001-09-04 Pharmaceutical formulation
SE0103565A SE0103565D0 (sv) 2001-10-25 2001-10-25 Pharmaceutical formulation
PCT/GB2002/001439 WO2002080902A1 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp

Publications (1)

Publication Number Publication Date
IL157955A0 true IL157955A0 (en) 2004-03-28

Family

ID=27354679

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15795502A IL157955A0 (en) 2001-04-02 2002-03-27 Solid pharmaceutical composition comprising 4-cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m toluidide and pvp

Country Status (21)

Country Link
US (1) US20040138299A1 (cs)
EP (1) EP1381358B1 (cs)
JP (1) JP2004525164A (cs)
KR (1) KR20030087048A (cs)
CN (1) CN1536993A (cs)
AT (1) ATE324886T1 (cs)
BR (1) BR0208421A (cs)
CA (1) CA2443040A1 (cs)
CZ (1) CZ20032647A3 (cs)
DE (1) DE60211139T2 (cs)
EE (1) EE200300476A (cs)
ES (1) ES2261655T3 (cs)
HU (1) HUP0303454A3 (cs)
IL (1) IL157955A0 (cs)
IS (1) IS6970A (cs)
MX (1) MXPA03008999A (cs)
NO (1) NO20034386L (cs)
NZ (1) NZ528284A (cs)
PL (1) PL365330A1 (cs)
SK (1) SK12032003A3 (cs)
WO (1) WO2002080902A1 (cs)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE307571T1 (de) * 2001-02-27 2005-11-15 Pharmazeutische formulierung enthaltend bicalutamid
SE0103424D0 (sv) * 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
US20050008691A1 (en) * 2003-05-14 2005-01-13 Arturo Siles Ortega Bicalutamide compositions
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
CN101128195A (zh) * 2005-02-23 2008-02-20 阿斯利康(瑞典)有限公司 用于递送增加的稳态血浆水平的比卡鲁胺
US7785629B2 (en) * 2005-06-21 2010-08-31 Helm Ag Bicalutamide-adsorbates, process for preparing same, and pharmaceutical compositions thereof
CN101272848B (zh) * 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
US20080045600A1 (en) * 2006-08-17 2008-02-21 Gawande Rahul S Bicalutamide compositions
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US10189957B2 (en) * 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
WO2009115954A1 (en) 2008-03-17 2009-09-24 Actelion Pharmaceuticals Ltd Dosing regimen for a selective s1p1 receptor agonist
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
CA2815460C (en) 2011-01-13 2017-04-18 Bio-Pharm Solutions Co., Ltd. Process for preparation of phenyl carbamate derivatives
KR101795562B1 (ko) 2011-12-27 2017-11-08 (주)바이오팜솔루션즈 뇌졸중의 치료 또는 예방에 사용되는 페닐카바메이트 화합물
TW201431570A (zh) 2012-11-22 2014-08-16 Ucb Pharma Gmbh 用於經皮投服羅替戈汀（Ｒｏｔｉｇｏｔｉｎｅ）之多天式貼片
CA2916183C (en) 2013-07-03 2022-03-29 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system with electronic component
JP6573913B2 (ja) * 2014-05-20 2019-09-11 エルテーエス ローマン テラピー−ジステーメ アーゲー ロチゴチンを含む経皮送達システム
EP4238580A3 (en) 2014-05-20 2023-10-25 LTS Lohmann Therapie-Systeme AG Transdermal delivery system including an interface mediator
JP6895755B2 (ja) 2014-05-20 2021-06-30 エルテーエス ローマン テラピー−ジステーメ アーゲー 経皮送達システムにおける活性薬剤の放出を調節するための方法
HUE051888T2 (hu) 2014-12-05 2021-03-29 Aragon Pharmaceuticals Inc Rákellenes készítmények
EA201791222A1 (ru) 2014-12-05 2017-09-29 Арагон Фармасьютикалз, Инк. Противораковые композиции
US10285948B2 (en) 2014-12-05 2019-05-14 Janssen Pharmaceutica Nv Anticancer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995019770A1 (en) * 1994-01-21 1995-07-27 Sepracor, Inc. Methods and compositions for treating androgen-dependent diseases using optically pure r-(-)-casodex
EP1027886B1 (en) * 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
GB9930839D0 (en) * 1999-12-30 2000-02-16 Pharmacia & Upjohn Spa Process for treating gynecomastia

Also Published As

Publication number Publication date
NO20034386L (no) 2003-11-28
IS6970A (is) 2003-09-29
BR0208421A (pt) 2004-03-30
SK12032003A3 (sk) 2004-03-02
US20040138299A1 (en) 2004-07-15
ATE324886T1 (de) 2006-06-15
DE60211139T2 (de) 2007-03-01
CN1536993A (zh) 2004-10-13
CZ20032647A3 (cs) 2004-09-15
NO20034386D0 (no) 2003-10-01
PL365330A1 (en) 2004-12-27
ES2261655T3 (es) 2006-11-16
DE60211139D1 (de) 2006-06-08
MXPA03008999A (es) 2004-02-12
NZ528284A (en) 2005-04-29
WO2002080902A1 (en) 2002-10-17
JP2004525164A (ja) 2004-08-19
KR20030087048A (ko) 2003-11-12
HUP0303454A2 (hu) 2004-01-28
EE200300476A (et) 2003-12-15
HUP0303454A3 (en) 2005-12-28
EP1381358A1 (en) 2004-01-21
EP1381358B1 (en) 2006-05-03
CA2443040A1 (en) 2002-10-17

Similar Documents

Publication Publication Date Title
PL365330A1 (en) Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono- m toluidide and pvp
WO2002067893A3 (en) Pharmaceutical formulation comprising bicalutamide
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
HU0102039D0 (en) Use of paclitaxel stabilized with albumin for the preparation of pharmaceutical compositions treating solid tumors and the pharmaceutical compositions obtained thereby
GEP20053673B (en) Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents
MXPA03011538A (es) Composicion medicinal que sustancialmente no causaria dano a la mucosa intestinal.
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BRPI0108435B8 (pt) formulação e uso de entecavir de baixa dose
DK1471892T3 (da) Transdermalt terapeutisk system til parkinsons sygdom, der inducerer höje rotigotinplasmaniveauer
DE60217367D1 (de) Nanopartikelzusammensetzungen enthaltend insulin
MXPA05011076A (es) Derivados de quinazolina para el tratamiento de cancer.
MXPA04003520A (es) Formulacion farmaceutica que comprende (r)-bicalutamida.
DE60004797D1 (de) Arzneimittel mit verzögerter wirkstoffabgabe enthaltend isoquercetin und ascorbinsäure
TW200505452A (en) Chemical compounds
SE0103839D0 (sv) Pharmaceutical formulation & product
MXPA04001912A (es) Aminobenzofenonas novedosas.
AU2002223970A1 (en) Kyberdrug as autovaccines with immune-regulating effects
SE0103838D0 (sv) Pharmaceutical formulation & product
SE0102887D0 (sv) New formulation
EP1374873B8 (en) The use of n-acetyl-d-glucosamine in the manufacture of pharmaceutical useful for supressing side-effect of radiotherapy and chemotherapy
CA2329665A1 (en) Treatment of depression and pharmaceutical preparations therefor
RU2003132064A (ru) Твердая фармацевтическая композиция, содержащая 4-циано-трифтор-3-(4-фторфенилсуфонил)-2-гидрокси-2-метилпропионо-м толуидид и pvp
BR0207572A (pt) Formulação farmacêutica, dose diária farmacêutica de bicalutamida administrável através das mucosas a um paciente, dispersão sólida de um polìmero entérico, e, uso de um polìmero entérico